Millennium Medical PublishingFLT3 Inhibitors in Acute Myeloid Leukemia: Increasing Options

In this Clinical Advances in Hematology & Oncology Q&A with Dr. Tapan M. Kadia, an associate professor at the MD Anderson Cancer Center, the current treatments for acute myeloid leukemia (AML) are discussed, with a specific focus on the targeted FLT3 approach, the role of the gene in AML, the differences among the approved FLT3 […]

Everyday HealthClinical Challenges: Pediatric ALL in Children With Obesity

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy seen in children and adolescents and young adults (AYAs). This article highlights two recent studies that provide novel evidence of the association between obesity and increased risk of high-risk B-ALL and the effectiveness of a non-pharmacologic intervention for reducing minimal residual disease (MRD) risk.

American Society of HematologyFDA Clears IND Application for Gamma Delta T-Cell Therapy

The investigational new drug (IND) application is for GDX012, which also received an FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The drug’s manufacturer, GammaDelta Therapeutics, is developing the T-cell platform in partnership with Takeda and will initiate a phase I study in late 2021 that will evaluate the treatment’s safety […]

American Society of Clinical OncologyFirst Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

It’s a battle of two heavyweights in this trial report from the Journal of Clinical Oncology, sharing the results of acalabrutinib (Calquence) compared to ibrutinib (Imbruvica) in treating chronic lymphocytic leukemia (CLL). Selected events of clinical interest included cardiac events, atrial fibrillation, ventricular tachyarrhythmias, hypertension, bleeding and major bleeding events, infections, and second primary malignancies […]

American Society of HematologyPosttransplantation MRD Monitoring in Patients w. AML by Next-Generation Sequencing Using DTA and Non-DTA Mutations

In this article from Blood Advances highlighted by helpful visual abstracts, two key points are discussed. First, patient-specific next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring using non-DTA mutations after allogeneic hematopoietic cell transplantation (alloHCT) is independently prognostic for relapse and survival. Second, the kinetics rather than a single time point should be further evaluated […]

Millennium Medical PublishingShould Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?

In this interview with Dr. Richard Furman, Professor of Medicine at New York-Presbyterian Weill Cornell Medicine, the importance of the CLL14 study is highlighted. In addition, Dr. Furman discusses the best use of venetoclax and whether anti-CD20 agents really add to the benefit of venetoclax treatment and whether a policy of watch and wait is […]

American Society of Clinical OncologyLong-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

In this Original Report from the Journal of Clinical Oncology, the authors conducted a phase I trial of autologous CD19 CAR T cells in children and young adults (CAYAs) with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) to discover whether the role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy can improve […]

American Society of HematologyUniversal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML

Published in Blood, this article presents initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany. The UniCAR platform uses targeting molecule TM123 and a single-chain variable fragment that is directed against the CD123 antigen, offering a potential new treatment option for patients with relapsed/refractory acute […]

American Society of HematologyEfficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

This Research Article from Blood – available as a PDF – discusses two main points. First, antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. The second point shows that, in patients treated with either Bruton’s tyrosine kinase inhibitors (TKIs) or venetoclax ± anti-CD20 […]